Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with pemetrexed and cisplatin as first-line treatment for driver gene-negative advanced non-squamous non-small cell lung cancer
ChiCTR1800016501Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Shandong First Medical University
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, pemetrexed and cisplatin in Non-small cell lung cancer (NS-NSCLC), sponsored by The Third Affiliated Hospital of Shandong First Medical University. Primary endpoint: progression-free survival. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranibpemetrexedcisplatin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR1800016501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016501.